ArticlePloS one2010
Circulating progenitor cell count for cardiovascular risk stratification: a pooled analysis.
Article in PloS one, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 95 citations in OpenAlex.
- Trial
- Hypoglycemia affects the changes in endothelial progenitor cell levels during insulin therapy in type 2 diabetic patients.Journal of endocrinological investigation · 2015Trial
- Difference in mobilization of progenitor cells after myocardial infarction in smoking versus non-smoking patients: insights from the BONAMI trial.Stem cell research & therapy · 2013Trial
- X-irradiated umbilical cord blood cells retain their regenerative effect in experimental stroke.Scientific reports · 2024Article
- Endothelial Progenitor Cells in Coronary Artery Disease: From Bench to Bedside.Stem cells translational medicine · 2022Review
- Assessment of Serum Neopterin as a Biomarker in Peripheral Artery Disease.Diagnostics (Basel, Switzerland) · 2021Article
- RNA sequencing of blood in coronary artery disease: involvement of regulatory T cell imbalance.BMC medical genomics · 2021Article
- Circulating stem cells and cardiovascular outcomes: from basic science to the clinic.European heart journal · 2020Review
- Mobilization of Stem and Progenitor Cells in Septic Shock Patients.Scientific reports · 2019Observational
- CD34Heart and vessels · 2018Article
- Associations between endothelial progenitor cells, clinical characteristics and coronary restenosis in patients undergoing percutaneous coronary artery intervention.BMC research notes · 2018Article
- Sex Differences in Circulating Progenitor Cells.Journal of the American Heart Association · 2017Article
- Association between echocardiographic epicardial fat thickness and circulating endothelial progenitor cell level in patients with stable angina pectoris.Clinical cardiology · 2017Article
- Chronic stress is associated with reduced circulating hematopoietic progenitor cell number: A maternal caregiving model.Brain, behavior, and immunity · 2017Article
- Age and Human Regenerative Capacity Impact of Cardiovascular Risk Factors.Circulation research · 2016Article
- Circulating Progenitor Cells Identify Peripheral Arterial Disease in Patients With Coronary Artery Disease.Circulation research · 2016Article
- Reduced levels of circulating progenitor cells in juvenile idiopathic arthritis are counteracted by anti TNF-α therapy.BMC musculoskeletal disorders · 2015Article
- Circulating CD34+ progenitor cells and risk of mortality in a population with coronary artery disease.Circulation research · 2015Article
- Regenerative principles enrich cardiac rehabilitation practice.American journal of physical medicine & rehabilitation · 2014Review
- Circulating progenitor cells in hypertensive patients with different degrees of cardiovascular involvement.Journal of human hypertension · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 7 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCirculating progenitor cells (CPC) contribute to the homeostasis of the vessel wall, and a reduced CPC count predicts cardiovascular morbidity and mortality. We tested the hypothesis that CPC count improves cardiovascular risk stratification and that this is modulated by low-grade inflammation. METHODOLOGY/PRINCIPAL
findingsWe pooled data from 4 longitudinal studies, including a total of 1,057 patients having CPC determined and major adverse cardiovascular events (MACE) collected. We recorded cardiovascular risk factors and high-sensitive C-reactive protein (hsCRP) level. Risk estimates were derived from Cox proportional hazard analyses. CPC count and/or hsCRP level were added to a reference model including age, sex, cardiovascular risk factors, prevalent CVD, chronic renal failure (CRF) and medications. The sample was composed of high-risk individuals, as 76.3% had prevalent CVD and 31.6% had CRF. There were 331 (31.3%) incident MACE during an average 1.7+/-1.1 year follow-up time. CPC count was independently associated with incident MACE even after correction for hsCRP. According to C-statistics, models including CPC yielded a non-significant improvement in accuracy of MACE prediction. However, the integrated discrimination improvement index (IDI) showed better performance of models including CPC compared to the reference model and models including hsCRP in identifying MACE. CPC count also yielded significant net reclassification improvements (NRI) for CV death, non-fatal AMI and other CV events. The effect of CPC was independent of hsCRP, but there was a significant more-than-additive interaction between low CPC count and raised hsCRP level in predicting incident MACE. CONCLUSIONS/SIGNIFICANCE: In high risk individuals, a reduced CPC count helps identifying more patients at higher risk of MACE over the short term, especially in combination with a raised hsCRP level.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.